Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib in Advanced Hepatocellular Carcinoma
NCT00355238Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of brivanib in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Primary endpoints: Progression Free Survival Rate at 6 Months and Number of Participants Experiencing Adverse Events up to 34 months. Started Dec 2006; status: completed.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00355238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00355238.